Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New risk tool aims to take the guesswork out of sarcoma treatment choices

NCT ID NCT05741944

Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a tool called PERSARC that gives soft-tissue sarcoma patients personalized information about the risks and benefits of different treatment options. 120 adults with high-grade sarcoma in their arms or legs will either get standard care or care using PERSARC. The goal is to see if the tool helps patients feel more informed and less conflicted about their treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PERSARC risk prediction tool
What this could lead to
If successful, this tool could help patients and doctors make clearer, more personalized treatment decisions for soft-tissue sarcoma.
What could go wrong
This is a small, early-stage study focused on decision-making, not on curing or treating the cancer itself. The tool may not improve outcomes or be widely adopted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Aug 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients \>= 18 years * Histologically diagnosed with grade 2-3 STS in their extremities. * Who do not have a treatment plan yet * Dutch fluency and literacy * Mentally competent * Signed informed consent * Patient owns a phone with internet access (WiFi) Exclusion Criteria: * Patient that are treated without curative intent * Patient that needs to be treated with chemotherapy or isolated limb perfusion * Patients were surgery is not indicated * Sarcoma subtypes not included in the PERSARC risk assessment tool In summary: patients with sarcoma subtypes and/or patients that need to be treated with other treatment modalities than those included in the PERSARC risk assessment tool are excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Predictive cancer model are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Predictive cancer model Soft tissue sarcoma

Contacts and locations

Locations

  • Erasmus MC

    Rotterdam, South Holland, 3015GD, Netherlands

  • Leiden University Medical Center

    Leiden, South Holland, 2333ZA, Netherlands

  • Maastricht UMC

    Maastricht, Limburg, 6229HX, Netherlands

  • Netherlands Cancer Institue

    Amsterdam, North Holland, 1066CX, Netherlands

  • Radboud UMC

    Nijmegen, Gelderland, 6525GA, Netherlands

  • UMC Groningen

    Groningen, Provincie Groningen, 9713GZ, Netherlands

  • UMC Utrecht

    Utrecht, Utrecht, 3584CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.